Board summary
Key figures
25,790
Registered population
54.4% aged 18–64
26.3%
Aged 65+
ICB 19.9% · England 17.9%
6.3%
Ethnic minority (non-White)
2.9% Asian · England 9.6%
0.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~135
Core20 residents (est.)
Resident basis; registered basis ~132 · see page 3
4,474
Hypertension register
+2.63% in 3 yrs · England +5.60%
164
SMI register
14.8% of Dartford's
428
COPD register
Reviews -9.60% in 3 yrs
Forecast to 2030
4,773
Hypertension patients, 2030
+299 on today
94.4%
QRISK ≥20% on statins, 2030
+11.97pp over 3 yrs
6.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage dropped sharply over three years.
Annual reviews reached 48.7% (England 65.7%) after falling 28.3% over 2023 to 2025, leaving 769 of 1,500 register patients unreviewed.
COPD and dementia registers contracted against national growth.
Over 2023 to 2025, COPD prevalence fell 10.5% to 1.7% (England +2.6%) and dementia fell 4.3% to 1.2% (England +6.0%), warranting coding review.
Under-80 hypertension control and SMI checks outpace England.
Under-80 blood pressure control reached 71.5% (+12.7 pp over 2023 to 2025; England 67.8%), while SMI blood pressure and BMI checks reached 85.2%.
Population, age and ethnicity
Patients aged 65+ make up 26.3% of registrations, exceeding borough and England benchmarks
LMN PCN serves 25,790 registered patients, of whom 26.3% (6,778 patients) are aged 65+, above Dartford (15.1%), NHS Kent and Medway ICB (19.9%), and England (17.9%). By practice, Jubilee Medical Centre records 27.5% aged 65+ and Meopham Medical Centre records 24.4%. Census resident data indicates 93.7% are White (Dartford 74.5%, ICB 88.6%, England 81.1%), with a 6.3% ethnic minority share. Projected population growth to 2030 is 0.8% under an unverified method, trailing Dartford (9.1%), the ICB (6.0%), and England (2.3%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Dartford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Dartford LA) | 2,006 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Dartford LA) | 1,000 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Dartford LA) | 14.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.5% across the PCN and concentrated entirely at Jubilee Medical Centre
LMN PCN records an average IMD decile of 7.1, compared to 6.0 in Dartford, 5.4 in NHS Kent and Medway ICB, and 5.5 in England. Its Core20 share is 0.5%, sitting below Dartford (9.8%), the ICB (17.1%), and England (21.0%). Workload is concentrated at Jubilee Medical Centre (0.8% share; 132 estimated patients), whereas Meopham Medical Centre records 0.0%. Resident modelling indicates 135 people across 1 decile-2 LSOA. With Core20 prevalence well below benchmarks, outreach could focus on the small cohort concentrated at the single affected practice.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
164
SMI register
0.64% recorded prevalence
124
Learning disability register
0.48% recorded prevalence
12
Care homes, 454 beds
In the PCN catchment
8.6%
Provide unpaid care
Dartford, Census 2021
The PCN records 124 learning disability patients (0.5%) and 164 severe mental illness patients (0.6%), alongside 12 catchment care homes with 454 beds. Both registers trail Dartford (0.6% and 0.8%), NHS Kent and Medway ICB (0.6% and 0.9%), and England (0.6% and 1.0%). Crude prevalence differences do not establish under-detection, but may prompt review of diagnostic recording across practices.
Severe mental illness: physical health checks
Annual SMI checks show BP (85.2%) and BMI (85.2%) above England (83.4% and 82.1%). Smoking cessation support fell 2.2 pp over 2023 to 2025 (England +0.1 pp) to 96.5%, dipping to 90.4% at Meopham Medical Centre.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,474
Hypertension register
+2.63%
Register growth, 3 yrs
Dartford +7.12% · England +5.60%
+12.66pp
BP control, under 80
≤140/90 · +3.13pp aged 80+
+299
More patients by 2030
Forecast 4,773 (18.26%)
Hypertension case-finding and control
Hypertension register prevalence is 17.3% (4,474 patients), above England (15.2%), Dartford (15.9%), and NHS Kent and Medway ICB (16.2%). Blood pressure monitoring reached 92.0% (England 90.0%). For patients aged under 80, blood pressure control was 71.5% after a 12.7 pp rise over 2023 to 2025 (England +2.1 pp). For patients aged 80 and over, control was 78.1%, below England (81.2%), Dartford (79.0%), and NHS Kent and Medway ICB (78.3%), with Jubilee Medical Centre recording 77.0% and Meopham Medical Centre recording 80.3%. Blood pressure control among patients aged 80 and over trails national and local benchmarks across both member practices.
Lipids and statins
Lipid-lowering therapy coverage is 60.9% for patients with QRISK ≥ 20% (England 63.6%, Dartford 64.2%, NHS Kent and Medway ICB 61.4%) and 68.5% for patients with CKD (England 70.3%, Dartford 74.3%, NHS Kent and Medway ICB 69.2%). Secondary prevention treatment rates trail national benchmarks in both high-risk cardiovascular cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 52,846 | £1.50 | £1.90 | £1.86 | £79,269 |
| Cardiovascular (all), 2025 | 68,267 | £3.78 | £3.57 | £3.33 | £258,049 |
In 2026, the PCN prescribed 52,846 items for lipid-regulating drugs at £1.50 per item, below England (£1.86), Dartford (£1.79), and NHS Kent and Medway ICB (£1.90), spending £19,025 less than at England's unit cost across 52,846 items. Prescribing unit costs remain lower than comparators, though unit cost does not measure treatment appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−28.33%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.01%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 19.3 pp (a 28.3% relative drop) over 2023 to 2025 to 48.7%, trailing Dartford (60.8%) and England (65.7%), leaving about 770 of 1,500 registered patients unreviewed; Jubilee Medical Centre achieved 40.0% while Meopham Medical Centre reached 63.2%. Over 2023 to 2025, COPD reviews fell 9.6% to 74.8% (England +2.8%), while COPD prevalence contracted 10.5% to 1.7% (England +2.6%).
Cancer register and children's immunisation
Cancer prevalence is 5.6% (1,456 patients), above Dartford (3.3%) and England (3.8%). In Q1 2025/26, 6-in-1 coverage at 24 months reached 98.3% (England 92.2%). At age 5, coverage was 87.9% across MMR dose 1, MMR dose 2, and the 4-in-1 pre-school booster (cohort of 58 children), each sitting 7.1 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
LMN PCN recorded 5.6% cancer prevalence (1,456 patients), with three-year growth of +5.8% over 2023 to 2025 (England +9.0%). Cervical screening reached 75.6% (Meopham Medical Centre 78.2%, Jubilee Medical Centre 73.9% vs England 66.8%) and breast screening reached 77.5% (England 69.9%). Across NHS Kent and Medway ICB in 2022, 55.6% of cancers were diagnosed at stage 1 or 2 (4,661 of 8,384 staged cancers; England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028, requiring 1,627 extra early diagnoses annually. Staging data is ICB-level with 63.6% known-stage completeness (England 67.0%), not PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Dartford and Gravesham NHS Trust achieved 63.6% on the 62-day cancer standard (21.4 pp below the 85.0% standard), trailing Medway NHS Foundation Trust (81.6%), NHS Kent and Medway Integrated Care Board (75.9%), and England (71.2%). Faster diagnosis (28-day FDS) reached 78.1% (England 79.3%) and 31-day combined treatment was 97.5% (England 92.5%). Diagnostic tests waiting 6+ weeks reached 8.4% (England 23.1%), with colonoscopy at 0.4%, non-obstetric ultrasound at 10.9%, and cystoscopy at 19.0%. These acute waiting times describe provider performance, not PCN performance.
| Pathways within standard (%) | Dartford and Gravesham | Medway | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 77.77 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 99.62 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 81.64 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | Medway | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 0.68 | 21.40 |
| CT | 2.08 | — | 0.00 | 9.92 |
| Echocardiography | 3.90 | — | 36.62 | 28.48 |
| Colonoscopy | 0.40 | — | 1.88 | 30.83 |
| Gastroscopy | 0.00 | — | 3.32 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 14.20 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026, Kent residents recorded 265,905 community care activities, 210,170 care contacts (65.8% with adults aged 65+), and 59,360 referrals across 60,605 active patients; NHS Kent and Medway Integrated Care Board recorded 297,595 activities and 254,055 contacts. These experimental figures describe wider system activity, not confirmed PCN patient volume.
Practice variation and patient experience
Phone access diverges by 30.2 percentage points between practices alongside vaccination lags
In 2025/26, QOF overall achievement reached 93.8% at Jubilee Medical Centre and 93.9% at Meopham Medical Centre (England 92.5%). Vaccination and immunisation achievement trailed England (55.2%) at 45.0% at Jubilee Medical Centre and 50.2% at Meopham Medical Centre (a 5.2 pp range). Vaccination personalised care adjustments were 7.4% at Jubilee Medical Centre and 4.4% at Meopham Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Meopham | 90 | 0.0 | 51.3% | 79.2% | 82.0% |
| Jubilee | 112 | 0.8 | 21.2% | 75.4% | 63.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year trajectories trailed England on 10 of 25 measures despite mental health gains
Over 2023 to 2025, three-year trajectories trailed England on 10 of 25 compared measures. The steepest relative falls occurred in annual asthma reviews, down 28.3% (England +4.4%), COPD prevalence, down 10.5% (England +2.6%), COPD reviews, down 9.6% (England +2.8%), and dementia prevalence, down 4.3% (England +6.0%). Conversely, key strengths emerged in physical health checks for severe mental illness: alcohol recording rose 39.7 pp (England +5.4 pp) and BMI checks rose 24.4 pp (England +5.1 pp), alongside under-80 blood pressure control rising 21.5% (England +3.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD register
COPD reviews
Dementia register
Cancer register
Alcohol record (psychosis)
BMI record (SMI)
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Dartford | Asset | PCN | Dartford |
|---|---|---|---|---|---|
| Care homes (catchment) | 12 (454 beds) | n/a | Schools (catchment) | 44 | n/a |
| Children's centres | 2 | 7 | Places of worship | 26 | 41 |
| Libraries | 6 | 7 | Homelessness support (VCS) | n/a | 1 |
| Day centres (VCS) | 5 | 5 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | 1 | 3 | Primary schools (LA maintained) | 7 | 6 |
| Primary academies | 6 | 22 | Special schools | 1 | no data |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall recovery
Asthma review coverage is 48.7% (Dartford 60.8%, England 65.7%) after a 28.3% drop over 2023 to 2025, leaving 769 of 1,500 registered patients unreviewed. For discussion: practices could run a structured asthma review recall using a single template and flexible slots, prioritising Jubilee Medical Centre. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD register and review audit
COPD prevalence is 1.7% (428 patients; Dartford 1.6%, England 1.9%; Range -12 to +61) after a 10.5% drop over 2023 to 2025; reviews fell 9.6% to 74.8% (England 76.4%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Learning disability register validation
Learning disability prevalence is 0.5% (124 patients; +10.1% over 2023 to 2025), below Dartford, ICB, and England (each 0.6%), with a modelled gap of Range +21 to +28. For discussion: practices could validate learning disability coding and cross-check registers with social-care or special-school records where data sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult anticipatory care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 case-finding (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation support audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older hypertension control audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster and MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register and pathway review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephony and triage workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall recovery (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · COPD register and review audit (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
